|
BioVentrix ~
$7,040,000 Series B Preferred Stock ~
May 2006
BioVentrix is a privately held
medical device company that manufactures and develops solutions
for the surgical treatment of congestive heart failure, a
disease that affects over 5 million people in the US alone. Its
first product, the Blue Egg, is used for the surgical
restoration of the left ventricle.
The Company is transitioning a
successful open surgical technique into a minimally invasive
cardiac catheterization procedure. Through a Series B financing,
Taglich Brothers provided BioVentrix capital it sought for
growth in addition to help develop and commercialize the next
generation of minimally invasive ventricular restoration
techniques.
The information
contained herein does not constitute a solicitation of any order
to buy or sell any securities. The information provided herein
may be displayed and printed for your personal, noncommercial
use only. You may not reproduce, retransmit, distribute,
disseminate, sell, publish, broadcast or circulate the
information to anyone, without the express written consent of
Taglich Brothers, Inc.
|
